<DOC>
	<DOCNO>NCT01552044</DOCNO>
	<brief_summary>The objective study evaluate effect spironolactone 16 patient present chronic non-resolutive central serous chorioretinitis ( CSCR ) evaluate whether spironolactone resolve sub retinal fluid patient . CSCR major cause visual loss young population . It characterize sub retinal fluid retina retinal pigment epithelial detachment . The exact cause disease remain unknown choroidopathy suggest . Moreover , corticotherapy stress know risk factor CSCR . Our preclinical study demonstrate mineralocorticoid pathway could involve control choroidal blood flow . The investigator propose evaluate mineralocorticoid receptor antagonist spironolactone treatment CSCR . Criteria efficacy Endpoint : reduction subretinal fluid ≥ 40 micron Secondary endpoint : visual acuity gain ≥ 15 EDTRS letter</brief_summary>
	<brief_title>Effect Spironolactone Treating Chronic Non-resolutive Central Serous Chorioretinitis</brief_title>
	<detailed_description>This prospective placebo control cross study include 16 patient</detailed_description>
	<mesh_term>Chorioretinitis</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Patient 18 60 year CSCR affect macula nonresolutive least 3 month Patients give sign informed consent Vital prognosis non engage next 6 month . Other ocular pathology Neovascularization , Diabetes Uveitis Ocular surgery last 3 month Allergy fluorescein indocyanine green Pregnancy contraception Renal liver insufficiency Kaliemia ≥ 5.5 mmol/l Criteria efficacy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>retina</keyword>
</DOC>